Accumulating evidence about the interaction between human microbiota and therapeutic-related substances, especially for clinical used drugs, deepens and broadens our understanding in the role of "our second genome" in human health and diseases, and opens a new window for managing/treating human healthy problems/diseases by manipulating microbiota-human interactions.
A centralized and standardized database to catalog Microbiota-Active Substances Interactions (MASIs) will be very useful for related research fields, including microbiota-related pharmaceutical research, food and nutrition research, clinical pharmacy, health management studies. Here, the MASI database is developed to cater this urgent need by providing manually curated MASIs data from scientific literature.
Ref-1. Ramy K Aziz, Rama Saad, and Mariam R Rizkallah. PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs. BMC Bioinformatics 2011; 12(Suppl 7): A10. Resource URL: http://www.pharmacomicrobiomics.com
Ref-2. Yorick Janssens, Joachim Nielandt, Antoon Bronselaer, et al. Disbiome Database: Linking the Microbiome to Disease. BMC Microbiol. 2018; 18(1):50. Resource URL: https://disbiome.ugent.be/home
Ref-3. Liang Cheng, Changlu Qi, He Zhuang, et al. gutMDisorder: A Comprehensive Database for Dysbiosis of the Gut Microbiota in Disorders and Interventions. Nucleic Acids Res 2020; 48(D1):D554-D560. Resource URL: http://bio-annotation.cn/gutMDisorder/home.dhtml